Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.